Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Survivin Gene as a Potential Marker in Premalignant and Malignant Lesions of Oral Cavity

Lingamdenne Paul Emerson and Pallipamu Prakash Babu

In a developing country where most of the people live in rural areas, Oral cancer management is a challenge with most of the cases presenting late. Carcinogenesis is a multistage process involving the activation of oncogenes and the inactivation of tumour suppressor genes. Biomarkers are important in establishing an accurate diagnosis and also can provide prognostic data. Survivin, a member of the inhibitor of apoptosis (IAP) protein family that inhibits caspases and blocks cell death, is highly expressed in most cancers and is associated with a poor clinical outcome. Survivin has consistently been identified by molecular profiling analysis to be associated with high tumour grade cancers, disease survival and recurrence. Polymorphisms in the survivin gene are emerging as powerful tools to study the biology of the disease and have the potential to be used in disease prognosis and diagnosis. The survivin gene polymorphisms have also been reported to influence tumour aggressiveness as well as survival of cancer patients. The differential expression of survivin in cancer cells compared to normal tissues and its role as a nodal protein in a number of cellular pathways make it a high target for different therapeutics. This review focuses on the literature on survivin, its role in cancerous and pre-cancerous lesions of oral cavity. It also gives a snapshot of its use in diagnosis, management and therapeutic management.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.